BillionToOne, Inc. (BLLN)
NasdaqGS · USD · Healthcare · Diagnostics & Research
$111.47 (+3.43%) as of
Key statistics
- Market cap
- 5.26B
- P/E (TTM)
- 176.93
- Forward P/E
- 75.06
- EPS (TTM)
- 0.63
- Dividend yield
- 0.00%
- 52-week range
- 61.96 – 150.44
- Revenue (TTM)
- 397.41M
- Profit margin
- 8.35%
- Analyst target
- $129.00
- Volume
- 404.71k
About BillionToOne, Inc.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Menlo Park, CA, United States
- Employees
- 713
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.